Serologic Profile of Donors In Argentina

by | May 26, 2023 | Publications

Transplant Proc. 2023 May 23:S0041-1345(23)00247-6. doi: 10.1016/j.transproceed.2023.03.076. Online ahead of print.


BACKGROUND: Constructing serologic profiles of donors is the first step in establishing traceability in the donation and transplant process. These data allow us to implement various strategies to enhance the recipients’ quality of care. We present the serologic profiles of donors in Argentina between 2017 and 2021.

METHODS: Donation processes initiated in 2017 to 2021 and registered in the National Information System of Procurement and Transplantation of the Argentine Republic were selected. The presence of complete serologic studies was considered an inclusion criterion. The serologic variables for viruses included HIV, human T-cell lymphotropic virus (HTLV), cytomegalovirus (CMV), hepatitis B virus (HBV), and hepatitis C virus (HCV). Those for bacteria included Treponema pallidum and the genus Brucella, and those for parasites included Trypanosoma cruzi and Toxoplasma gondii.

RESULTS: A total of 18,242 processes were initiated in the period 2017 to 2021. A total of 6015 processes had documented complete serologic studies. Most donors came from 2 jurisdictions: Buenos Aires (27.72%) and CABA (15.13%). Cytomegalovirus (84.70%) and T. gondii (40.94%) were the most prevalent serologies. We identified 0.25% reactive serologies for HIV, 0.24% for HTLV, 0.79% for HCV, and 2.49% for T. pallidum. In reference to HBV markers, 0.19% of donors presented Ag HBs, and the Ac HBc + Ac HBs association was observed in 2.31% of donors. Reactive serology for brucellosis was demonstrated in 1.11% of donors. Reactive serology for Chagas disease was found in 0.9% of donors.

CONCLUSIONS: Given the wide variation in seroprevalence in the different jurisdictions of the country, the jurisdictional and national levels of government should be responsible for monitoring changes in behavior that require modification of selection and prevention strategies.

PMID:37230902 | DOI:10.1016/j.transproceed.2023.03.076

Other publications you may be interested in…

HTLV-1 Disease

HTLV-1 Disease

HTLV-1 Disease Abstract The years 2020 and 2021 will remain memorable years for many reasons [...]. Click here to...

read more